Cell differentiation, reprogramming and malignant transformation are major events characterized by remarkable changes in the epigenome and involve remodeling of DNA methylation patterns. In cancer tissues, DNA methylation patterns are drastically different from those in normal tissues. Two major events are observed, (i) global DNA hypomethylation in cancer affecting predominantly repetitive DNA sequences, and (ii) gene-specific hypermethylation of CpG islands affecting hundreds of genes. The mechanisms how these cancer-associated DNA methylation patterns arise are largely unknown. In 2009, it was reported that a sixth DNA base, 5-hydroxymethylcytosine, is present in substantial amounts in certain mammalian cell types. 5-hydroxymethylcytosine (5hmC) is created from 5-methylcytosine (5mC) by enzymatic oxidation carried out by the TET family of proteins. One model proposes that 5hmC is an intermediate in DNA demethylation. Our hypothesis is that defects in the 5mC oxidation pathway are responsible for altered DNA methylation patterns in human tumors. We have established methodology for precise quantification and genome-wide mapping of 5mC and 5hmC. Our goal is to determine the level and the genomic distribution of 5hmC in normal human tissues and in malignant tumors. These data will be compared directly with the distribution of 5mC in the same tissues. We will focus primarily on two tumor types: (1) human grade II/III astrocytomas, because these tumors frequently contain mutations in isocitrate dehydrogenases (IDH1 or IDH2), an enzymatic activity potentially impacting on the 5mC oxidation pathway; and (2) myelodysplastic syndrome (MDS), because this malignancy often is characterized by mutations in one of the TET genes, TET2.
The third Aim will focus on functional studies of TET and TET-associated proteins and their aberrations in cancer.
DNA cytosine-5 methylation patterns in cancer are aberrant and are characterized by frequent hypermethylation of CpG islands. It is unknown how these changes in tumors are initiated. Recently, it has been shown that 5-methylcytosine can be oxidized enzymatically to 5-hydroxymethylcytosine. In this application, we propose that changes in 5-hydroxymethylcytosine patterns are hallmarks of malignant transformation and are related to the aberrant DNA cytosine methylation patterns seen in tumors. We will analyze this novel epigenetic mark as well as 5-methylcytosine in normal and malignant tissues. We will also investigate if and how mutations affecting the 5- methylcytosine oxidation pathway have an effect on genomic methylation patterns in human tumors. Functional studies of 5-methylcytosine oxidases (TET proteins) and their associated factors will support these studies so that a comprehensive picture of the importance of this pathway in human tumorigenesis can be obtained.
Showing the most recent 10 out of 14 publications
